Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | 阶段
第 1 阶段
|
Date Added 2017-10-18 |
地点
Arizona, United States
California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States 澳大利亚 日本 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
mRNA-4157, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03310008 |
TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | 阶段
第 1 阶段
|
Date Added 2017-10-16 |
地点
比利时
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NKR-2 cells |
标签
MSS/ MMRp
|
| NCT ID NCT03297606 |
Title加拿大剖析和靶向制剂利用试验（CAPTUR） | 阶段
第二阶段
|
Date Added 2017-09-29 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03296137 |
TitleAdoptive Cell Therapy Across Cancer Diagnoses | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2017-09-28 |
地点
丹麦
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT03290937 |
TitleUtomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2017-09-25 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, Irinotecan Hydrochloride, Utomilumab |
标签
MSS/ MMRp
|
| NCT ID NCT03289962 |
TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | 阶段
第 1 阶段
|
Date Added 2017-09-21 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States 比利时 加拿大 德国 荷兰 西班牙 瑞典 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, Autogene cevumeran, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT03280511 |
Title对切除的高危结肠癌患者进行辅助加压腹腔内气溶胶化疗 (PIPAC) | 阶段
第二阶段
|
Date Added 2017-09-12 |
地点
丹麦
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
PIPAC |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03239145 |
TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | 阶段
第 1 阶段
|
Date Added 2017-08-03 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Trebananib |
标签
MSS/ MMRp
|
| NCT ID NCT03223779 |
TitleTAS-102 加放射疗法治疗结直肠癌肝转移患者肝脏的研究 | 阶段
第 1 阶段
|
Date Added 2017-07-21 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | 阶段
Phase 1, Phase 2
|
Date Added 2017-07-14 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
标签
MSS/ MMRp
|
